secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001178670-25-000089
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance
--------------------------------------------------------------------------------

- Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.
- GAAP loss from operations $16M vs income $49M in Q2 2024; non-GAAP income from operations $95M.
- Raised FY2025 guidance: TTR revenue to $2.175-2.275B; total net product revenue to $2.65-2.8B (+27% at midpoint).
- ~1,400 ATTR-CM patients on AMVUTTRA as of June 30; approvals secured in EU, UK, Brazil, and Japan.
- Initiated TRITON-CM Phase 3 trial for nucresiran in ATTR-CM; received FDA Fast Track designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/0001178670-25-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/alny-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001178670-25-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer